Monitor the final pricing supplement for coupon rates and total offering size, the key variable is how much Teva saves on interest versus the called notes. The refinancing is credit-neutral to mildly positive for bonds but does not change the equity thesis. Watch for any subsequent 8-K confirming the closing and redemption execution.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 8 $36.76entry
- T+1 · 2mo ago +0.24%α +0.71% · $36.85
- T+5 · 2mo ago +6.77%α +7.89% · $39.25
- T+20 · 6w ago +6.45%α +4.73% · $39.13
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva is launching a multi-tranche debt offering of EUR and USD senior notes across five maturities (2032-2037), with proceeds intended to fund the conditional redemption of up to ~$4.5B in higher-coupon notes (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, plus portions of 4.750% 2027s and 4.375% 2030s). This is a liability management refinancing that reduces near-term debt costs and extends maturities, but the offering size and final coupon rates are undisclosed in this preliminary filing. The transaction is credit-positive for bondholders (removing expensive debt) but neutral for equity holders as it does not change the fundamental business outlook or leverage trajectory beyond the refinancing math.
Key Facts
- Teva is offering five series of senior unsecured notes: EUR 2033s, EUR 2036s, USD 2032s, USD 2034s, and USD 2037s.
- Proceeds will fund conditional redemptions of up to $1.25B of 6.750% 2028 USD notes, $398M of 7.875% 2029 USD notes, €758M of 7.375% 2029 EUR notes, $450M of 4.750% 2027 USD notes, and €1.25B of 4.375% 2030 EUR notes.
- The offering is conditioned on the redemptions, but the redemptions are not conditioned on the offering.
- Teva had $16.65B of senior unsecured indebtedness outstanding as of June 30, 2026, and no secured debt.
- LTM net revenues were $17.315B and LTM Adjusted EBITDA was $4.56B as of June 30, 2026.
- The filing is preliminary, coupon rates, offering sizes, and final pricing are all placeholder values.
- The underwriters include BNP Paribas, Citigroup, Goldman Sachs, J.P. Morgan, BofA, HSBC, Mizuho, and others.
Financial Impact
Refinancing of up to ~$4.5B in higher-coupon debt with new notes at current market yields; exact interest savings depend on final pricing, which is undisclosed.
Risk Factors
- Offering size and coupon rates are undisclosed, actual terms may differ materially from market expectations.
- The offering is not conditioned on the redemptions, creating execution risk if market conditions shift.
- Teva's LTM net income attributable to Teva was only $706M, and the company reported a net loss of $207M in H1 2026, indicating thin earnings coverage of the enlarged debt base.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-384343 |
| Document: 0001193125-26-384343-index-headers.html | 0001193125-26-384343 |
| Document: 0001193125-26-384343-index.html | 0001193125-26-384343 |
| Document: 0001193125-26-384343.txt | 0001193125-26-384343 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers